Regeneron Pharmaceuticals, Inc. $REGN Position Cut by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 278,120 shares of the biopharmaceutical company’s stock after selling 4,079 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $210,890,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $95,976,000. Vise Technologies Inc. raised its position in Regeneron Pharmaceuticals by 22.4% in the 3rd quarter. Vise Technologies Inc. now owns 2,622 shares of the biopharmaceutical company’s stock valued at $1,989,000 after buying an additional 480 shares during the last quarter. Grandfield & Dodd LLC boosted its position in Regeneron Pharmaceuticals by 1.3% in the third quarter. Grandfield & Dodd LLC now owns 37,098 shares of the biopharmaceutical company’s stock worth $28,130,000 after purchasing an additional 470 shares during the last quarter. Summit Global Investments grew its position in shares of Regeneron Pharmaceuticals by 2.2% during the 3rd quarter. Summit Global Investments now owns 7,670 shares of the biopharmaceutical company’s stock valued at $5,816,000 after acquiring an additional 164 shares during the period. Finally, Invera Wealth Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 59.6% during the third quarter. Invera Wealth Advisors LLC now owns 787 shares of the biopharmaceutical company’s stock valued at $597,000 after purchasing an additional 294 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $927.89 on Monday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $591.52 and a 1 year high of $935.35. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.06 and a quick ratio of 3.66. The company’s 50-day moving average is $793.30 and its 200 day moving average is $738.05. The stock has a market capitalization of $95.54 billion, a P/E ratio of 20.49, a P/E/G ratio of 1.57 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. The business had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The business’s revenue was up 36.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $11.83 earnings per share. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be given a $0.94 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent research reports. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Robert W. Baird lifted their price objective on shares of Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the company a “neutral” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. increased their price objective on Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the stock an “overweight” rating in a report on Tuesday, October 6th. Evercore upped their price target on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Finally, Raymond James Financial upped their price objective on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $850.83.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, insider Andrew J. Murphy sold 4,147 shares of the firm’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider directly owned 47,833 shares of the company’s stock, valued at approximately $36,960,559.10. This trade represents a 7.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the sale, the director owned 603 shares of the company’s stock, valued at $512,550. This trade represents a 39.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,093 shares of company stock worth $6,506,845 in the last 90 days. Corporate insiders own 6.97% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.